A Wake-up Call from Down Under: Australia's Therapeutic Goods Administration Reschedules Psilocybin and MDMA
By Shane Pennington
Mar 1, 2023
How TGA's rescheduling of psilocybin and MDMA shines a bright light on DEA delinquency
By Shane Pennington
Mar 1, 2023
How TGA's rescheduling of psilocybin and MDMA shines a bright light on DEA delinquency
By Cassia Furman, Jason Adelstone
Feb 24, 2023
A bill passed in 2022 authorized California to enter into agreements with neighboring states allowing for interstate transfers between cannabis licensees, so long as the cannabis products don’t pass through a non-legal state. Could this be implemented? What are the risks?
By Krissy Atterholt
Feb 14, 2023
Michigan leads the Midwest in affording its communities local protection for psychedelic-based activities. This article gives a breakdown of notable moments in Michigan's psychedelic legislative history.
By Catie Wightman
Feb 13, 2023
In recent years, several CBD companies faced product liability lawsuits brought by consumers. Many of these cases were dismissed without prejudice or stayed until the FDA takes action to regulate CBD products. Now that the FDA said it will not take action to regulate CBD, could these cases be revived?
By Catie Wightman
Feb 9, 2023
With recent announcements from the FDA pushing CBD and hemp-derived products further into a legal gray area, can veterinarians recommend or sell these products for pets?
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.